Karyopharm Therapeutics (KPTI)

Its principal marketed product is XPOVIO, the brand name for selinexor. Selinexor is an oral selective inhibitor of nuclear export that is used in oncology settings, including multiple myeloma. By blocking XPO1, the drug is intended to retain tumor suppressor proteins and other growth-regulating molecules inside the nucleus, where they may help promote cancer cell death or reduce malignant cell survival. This mechanism differentiates Karyopharm from companies developing more conventional chemotherapy, antibody, or kinase inhibitor approaches.

Karyopharm’s business combines commercial execution with continued clinical development. The company markets XPOVIO while also evaluating nuclear export inhibition across additional cancer indications and treatment combinations. Its research reflects a broader effort in oncology to exploit vulnerabilities in the way cancer cells control signaling, protein trafficking, and stress responses.

As a commercial-stage pharmaceutical company, Karyopharm’s performance is shaped by product uptake, reimbursement, competitive treatment standards, clinical trial results, and regulatory decisions. Its focus on XPO1 inhibition gives it a specialized position within cancer drug development, with a strategy centered on expanding the clinical relevance of its nuclear export technology platform.